CHEANN LEGASPI: Open Payments
NPI 1720660848 · SANTA ANA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,885 in 75 payments from 10 companies in 2025. Trend: 2023 $1,579 · 2024 $1,737 · 2025 $1,885
Food & beverage: $1,698Education: $187
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 18 | $492 |
| Vanda Pharmaceuticals Inc. | 10 | $208 |
| E.R. Squibb & Sons, L.L.C. | 10 | $198 |
| ACADIA Pharmaceuticals Inc | 5 | $188 |
| Otsuka America Pharmaceutical, Inc. | 9 | $186 |
| Neurocrine BioSciences, Inc. | 7 | $166 |
| Alkermes, Inc. | 3 | $162 |
| ABBVIE INC. | 8 | $149 |
| Janssen Pharmaceuticals, Inc | 3 | $89 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
Products named: FANAPT, COBENFY, AUSTEDO XR, NUPLAZID, INGREZZA, VRAYLAR, REXULTI, LYBALVI.
Industry payments across CA — which companies pay providers there.
